Amarantus BioScience Holdings, Inc.
AMBS · OTC
12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.00 | -0.00 | 0.05 | -0.00 |
| FCF Yield | -456.63% | -164.18% | -2.80% | 28.76% |
| EV / EBITDA | -4.44 | -2.53 | -52.52 | 1.22 |
| Quality | ||||
| ROIC | 4.85% | 20.19% | -6.46% | 180.01% |
| Gross Margin | 100.00% | 0.00% | 100.00% | 100.00% |
| Cash Conversion Ratio | 0.94 | 0.97 | 0.13 | 0.06 |
| Growth | ||||
| Revenue 3-Year CAGR | 8.47% | -100.00% | – | – |
| Free Cash Flow Growth | 54.68% | -11,908.91% | -108.13% | 156.55% |
| Safety | ||||
| Net Debt / EBITDA | -4.22 | -1.93 | -45.53 | 1.03 |
| Interest Coverage | 0.00 | 0.00 | 0.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 0.00 | 0.00 | 0.00 | 0.00 |